Literature DB >> 30612951

What Makes a Kinase Promiscuous for Inhibitors?

Sonya M Hanson1, George Georghiou2, Manish K Thakur2, W Todd Miller3, Joshua S Rest4, John D Chodera5, Markus A Seeliger6.   

Abstract

ATP-competitive kinase inhibitors often bind several kinases due to the high conservation of the ATP binding pocket. Through clustering analysis of a large kinome profiling dataset, we found a cluster of eight promiscuous kinases that on average bind more than five times more kinase inhibitors than the other 398 kinases in the dataset. To understand the structural basis of promiscuous inhibitor binding, we determined the co-crystal structure of the receptor tyrosine kinase DDR1 with the type I inhibitors dasatinib and VX-680. Surprisingly, we find that DDR1 binds these type I inhibitors in an inactive conformation typically reserved for type II inhibitors. Our computational and biochemical studies show that DDR1 is unusually stable in this inactive conformation, giving a mechanistic explanation for inhibitor promiscuity. This phenotypic clustering analysis provides a strategy to obtain functional insights not available by sequence comparison alone.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABL; DDR1; DFG; Folding@home; Markov state model; crystallography; drug promiscuity; kinase inhibition; molecular dynamics; selectivity

Mesh:

Substances:

Year:  2019        PMID: 30612951      PMCID: PMC6632086          DOI: 10.1016/j.chembiol.2018.11.005

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  53 in total

Review 1.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

2.  Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments.

Authors:  Vladimir Vacic; Lilia M Iakoucheva; Predrag Radivojac
Journal:  Bioinformatics       Date:  2006-04-21       Impact factor: 6.937

Review 3.  Protein production and purification.

Authors:  Susanne Gräslund; Pär Nordlund; Johan Weigelt; B Martin Hallberg; James Bray; Opher Gileadi; Stefan Knapp; Udo Oppermann; Cheryl Arrowsmith; Raymond Hui; Jinrong Ming; Sirano dhe-Paganon; Hee-won Park; Alexei Savchenko; Adelinda Yee; Aled Edwards; Renaud Vincentelli; Christian Cambillau; Rosalind Kim; Sung-Hou Kim; Zihe Rao; Yunyu Shi; Thomas C Terwilliger; Chang-Yub Kim; Li-Wei Hung; Geoffrey S Waldo; Yoav Peleg; Shira Albeck; Tamar Unger; Orly Dym; Jaime Prilusky; Joel L Sussman; Ray C Stevens; Scott A Lesley; Ian A Wilson; Andrzej Joachimiak; Frank Collart; Irina Dementieva; Mark I Donnelly; William H Eschenfeldt; Youngchang Kim; Lucy Stols; Ruying Wu; Min Zhou; Stephen K Burley; J Spencer Emtage; J Michael Sauder; Devon Thompson; Kevin Bain; John Luz; Tarun Gheyi; Fred Zhang; Shane Atwell; Steven C Almo; Jeffrey B Bonanno; Andras Fiser; Sivasubramanian Swaminathan; F William Studier; Mark R Chance; Andrej Sali; Thomas B Acton; Rong Xiao; Li Zhao; Li Chung Ma; John F Hunt; Liang Tong; Kellie Cunningham; Masayori Inouye; Stephen Anderson; Heleema Janjua; Ritu Shastry; Chi Kent Ho; Dongyan Wang; Huang Wang; Mei Jiang; Gaetano T Montelione; David I Stuart; Raymond J Owens; Susan Daenke; Anja Schütz; Udo Heinemann; Shigeyuki Yokoyama; Konrad Büssow; Kristin C Gunsalus
Journal:  Nat Methods       Date:  2008-02       Impact factor: 28.547

4.  A conserved protonation-dependent switch controls drug binding in the Abl kinase.

Authors:  Yibing Shan; Markus A Seeliger; Michael P Eastwood; Filipp Frank; Huafeng Xu; Morten Ø Jensen; Ron O Dror; John Kuriyan; David E Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-24       Impact factor: 11.205

Review 5.  Targeting cancer with small molecule kinase inhibitors.

Authors:  Jianming Zhang; Priscilla L Yang; Nathanael S Gray
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

6.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

7.  Structural and biochemical studies of the PDGFRA kinase domain.

Authors:  Ling Liang; Xiao-E Yan; Yuxin Yin; Cai-Hong Yun
Journal:  Biochem Biophys Res Commun       Date:  2016-06-24       Impact factor: 3.575

8.  Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src.

Authors:  Sanjay B Hari; B Gayani K Perera; Pratistha Ranjitkar; Markus A Seeliger; Dustin J Maly
Journal:  ACS Chem Biol       Date:  2013-10-29       Impact factor: 5.100

9.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

Review 10.  Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?

Authors:  Zheng Zhao; Hong Wu; Li Wang; Yi Liu; Stefan Knapp; Qingsong Liu; Nathanael S Gray
Journal:  ACS Chem Biol       Date:  2014-04-29       Impact factor: 5.100

View more
  11 in total

1.  How Electrostatic Coupling Enables Conformational Plasticity in a Tyrosine Kinase.

Authors:  Cheng-Chieh Tsai; Zhi Yue; Jana Shen
Journal:  J Am Chem Soc       Date:  2019-09-13       Impact factor: 15.419

2.  Protein Ligand Interactions Using Surface Plasmon Resonance.

Authors:  Nichole O'Connell
Journal:  Methods Mol Biol       Date:  2021

3.  Independent Markov decomposition: Toward modeling kinetics of biomolecular complexes.

Authors:  Tim Hempel; Mauricio J Del Razo; Christopher T Lee; Bryn C Taylor; Rommie E Amaro; Frank Noé
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-03       Impact factor: 11.205

4.  Derivatization Design of Synthetically Accessible Space for Optimization: In Silico Synthesis vs Deep Generative Design.

Authors:  Gergely M Makara; László Kovács; István Szabó; Gábor Pőcze
Journal:  ACS Med Chem Lett       Date:  2021-01-07       Impact factor: 4.345

5.  Dasatinib-SIK2 Binding Elucidated by Homology Modeling, Molecular Docking, and Dynamics Simulations.

Authors:  Mingsong Shi; Lun Wang; Penghui Li; Jiang Liu; Lijuan Chen; Dingguo Xu
Journal:  ACS Omega       Date:  2021-04-15

Review 6.  Druggable Transient Pockets in Protein Kinases.

Authors:  Koji Umezawa; Isao Kii
Journal:  Molecules       Date:  2021-01-27       Impact factor: 4.411

7.  Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.

Authors:  Zhaoping Xiong; Minji Jeon; Robert J Allaway; Jaewoo Kang; Donghyeon Park; Jinhyuk Lee; Hwisang Jeon; Miyoung Ko; Hualiang Jiang; Mingyue Zheng; Aik Choon Tan; Xindi Guo; Kristen K Dang; Alex Tropsha; Chana Hecht; Tirtha K Das; Heather A Carlson; Ruben Abagyan; Justin Guinney; Avner Schlessinger; Ross Cagan
Journal:  PLoS Comput Biol       Date:  2021-09-14       Impact factor: 4.779

8.  Molecular modeling provides a structural basis for PERK inhibitor selectivity towards RIPK1.

Authors:  Chetan Chintha; Antonio Carlesso; Adrienne M Gorman; Afshin Samali; Leif A Eriksson
Journal:  RSC Adv       Date:  2020-01-02       Impact factor: 4.036

9.  Harnessing Protein-Ligand Interaction Fingerprints to Predict New Scaffolds of RIPK1 Inhibitors.

Authors:  Natália Aniceto; Vanda Marques; Joana D Amaral; Patrícia A Serra; Rui Moreira; Cecília M P Rodrigues; Rita C Guedes
Journal:  Molecules       Date:  2022-07-23       Impact factor: 4.927

10.  Two-step release of kinase autoinhibition in discoidin domain receptor 1.

Authors:  Douglas Sammon; Erhard Hohenester; Birgit Leitinger
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.